Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCIP subcutaneous benzathine penicillin G for secondary prophylaxis in rheumatic heart disease
ACTRN12624001383550Phase 2Recruiting
- Sponsor
- The Kids Research Institute Australia
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of benzylpenicillin in rheumatic heart disease (RHD) and rheumatic fever (RF), sponsored by The Kids Research Institute Australia. Primary endpoints: Acceptability of SCIP implementation, Intention to continue receiving SCIP as rheumatic heart disease prophylaxis after study end and 1 more. Started May 2026; status: recruiting.
02
Drugs
benzylpenicillin
03
Conditions
rheumatic heart disease (RHD)rheumatic fever (RF)
Beyond the preview
Go deeper on ACTRN12624001383550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624001383550.